Kennewick, Tonga Clinical Trials
A listing of Kennewick, Tonga clinical trials actively recruiting patients volunteers.
Found 53973 clinical trials
Sternal Cerclage (sternal bone closure after open heart surgery)
The purpose of the study is to learn which treatment option is better for patients who have multi-vessel coronary artery disease (blockages in more than one vessel supplying blood to the heart muscle).
- 1647 views
- 05 Feb, 2021
- 1 location
A trial evaluating TEPEZZA® in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
The overall objective is to investigate the safety, tolerability and effect on insulin-like growth factor-1 (IGF-1), inflammatory and fibrotic biomarkers of TEPEZZA® administered once every 3 weeks (q3W) for 24 weeks in the treatment of participants with diffuse cutaneous systemic sclerosis (dcSSc).
- 0 views
- 20 May, 2022
- 3 locations
A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children With Atopic Dermatitis (TRuE-AD3)
The purpose of the study is to assess the efficacy and safety of ruxolitinib cream in children with Atopic Dermatitis. This is a randomized, double-blind, Vehicle Controlled study. Participants will be randomized 2:2:1 to blinded treatment with ruxolitinib cream 0.75% ,1.5% , or vehicle cream, with stratification by baseline IGA …
- 0 views
- 11 May, 2022
- 20 locations
Study to evaluate HZN-825 in patients with Idiopathic Pulmonary Fibrosis (IPF)
The goal is to determine the efficacy, safety and tolerability for 360 patients with Idiopathic Pulmonary Fibrosis (IPF) assigned to either one of 2 dose regimens of HZN-825 (administered once daily (QD) or twice daily (BID)) or a placebo regimen for 52 weeks. Participants who complete the duration of this …
- 0 views
- 30 May, 2022
- 10 locations
A Trial Evaluating Different Dosing Durations of TEPEZZA® Treatment in Patients with Thyroid Eye Disease (TED)
The overall objective is to investigate the safety, tolerability and need for re-treatment of 3 different TEPEZZA® treatment durations (4, 8, or 16 infusions) in patients with TED.
- 0 views
- 04 Jun, 2022
- 7 locations
A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis
The purpose of this study is to evaluate the efficacy and safety of INCB054707 in participants with prurigo nodularis over a 16-week double-blind placebo-controlled treatment period, followed by a 24 -week single blind extension period.
- 0 views
- 08 Jun, 2022
- 22 locations
A trial evaluating Pegloticase administered with a shorter infusion duration in patients with Uncontrolled Gout receiving methotrexate.
The purpose of this study is to assess the safety, tolerability and efficicacy of pegloticase administered with a shorter infusion duration in participants with uncontrolled gout receiving methotrexate.
- 0 views
- 08 Jun, 2022
- 3 locations
A trial evaluating Pegloticase administered every 4 week with Co-administration of weekly doses of MTX (methotrexate) in patients with Uncontrolled Refractory Gout. (FORWARD OL)
Approximately 40 participants will be enrolled. The trial has a Screening period up to 35 days, followed by 4-week methotrexate (MTX) tolerability run-in. Treatment consists of pegloticase IV Q4 Wks dose for a total of 6 infusions (24 Weeks) with co-administered weekly oral MTX. Optional extension treatment (24-48 weeks) will …
- 0 views
- 10 Jun, 2022
- 4 locations
Feasibility of a Systems Approach for Alzheimer's Services Among Latinos Attending Primary Care Practices
The research team will train primary care practitioners from Kansas City clinics to enhance skills in cultural competence, dementia detection, treatment and referral to a Health Navigator among Latinos 65 and older with dementia. The Health Navigator will provide patient/caregiver dyads referred by Alianza Latina providers with care management, psychosocial …
- 0 views
- 09 Jun, 2022
- 1 location
A Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Malignancies
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, pharmacodynamics, and early clinical activity of single-agent INCB081776 (Part 1) and INCB081776 in combination with INCMGA00012 (Part 2).
- 0 views
- 28 Jun, 2022
- 10 locations